RT Journal Article SR Electronic T1 Thalidomide Radiosensitization of Normal Murine Hematopoietic but Not Squamous Cell Carcinoma or Multiple Myeloma Tumor Cell Lines JF In Vivo JO In Vivo FD International Institute of Anticancer Research SP 333 OP 339 VO 20 IS 3 A1 MICHAEL W. EPPERLY A1 EMILY E. GREENBERGER A1 DARCY FRANICOLA A1 SAMUEL JACOBS A1 JOEL S. GREENBERGER YR 2006 UL http://iv.iiarjournals.org/content/20/3/333.abstract AB Background: Thalidomide (TL), due to its anti-angiogenic effects, has been postulated to be a potential radiosensitizer of multiple myeloma and squamous tumors in vivo. Materials and Methods: To determine whether TL was a radiosensitizer, 32D cl 3 cells (hematopoietic progenitor) as well as SCC-VII (squamous cell carcinoma), OPM1 or OPM2 (multiple myeloma) tumor cells were irradiated to doses ranging from 0 to 8 Gy and then plated in 0, 50 or 150 μM TL in each of three protocols: i) 1 hour before irradiation; ii) 1 hour before irradiation and also in medium following irradiation; or iii) placed in TL containing medium following irradiation. Results: Using 150 μM TL (which did not stimulate cell growth) the 32D cl 3 cells had increased radiation sensitivity compared to the control irradiated cells. In contrast, the SCC-VII, OPM1 or OPM2 cells showed no detectable radiosensitization when incubated in TL before, during or after irradiation compared to the control irradiated cells. Conclusion: These results demonstrated that TL may be a selective radiosensitizer. Copyright © 2006 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved